Targeting histone methyltransferase EZH2 as cancer treatment

Journal of Biochemistry

Volumn 156, Issue 5, 2014, Pages 249-257

  Kondo, Yutaka ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Cancer; Epigenetics; EZH2; Polycomb; Treatment

Indexed keywords

POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; EZH2 PROTEIN, HUMAN; MOLECULAR LIBRARY;

BIOCHEMICAL ANALYSIS; CANCER CELL; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; EPIGENETICS; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; NEURAL STEM CELL; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; PATHOLOGY; PHARMACOLOGY;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; SMALL MOLECULE LIBRARIES;

EID: 84923109013     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvu054     Document Type: Review

References (60)

1. Kondo, Y., Shen, L., Yan, P.S., Huang, T.H., and Issa, J.P. (2004) Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc. Natl Acad. Sci. USA 101, 7398-7403
2. Sparmann, A. and van Lohuizen, M. (2006) Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6, 846-856
3. Kondo, Y., Shen, L., Cheng, A.S., Ahmed, S., Boumber, Y., Charo, C, Yamochi, T., Urano, T., Furukawa, K., Kwabi-Addo, B., Gold, D.L., Sekido, Y., Huang, T.H., and Issa, J.P. (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 40, 741-750
4. Cedar, H. and Bergman, Y. (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 10, 295-304
5. Natsume, A., Ito, M., Katsushima, K., Ohka, F., Hatanaka, A., Shinjo, K., Sato, S., Takahashi, S., Ishikawa, Y., Takeuchi, I., Shimogawa, H, Uesugi, M., Okano, H., Kim, S.U., Wakabayashi, T., Issa, J.P., Sekido, Y., and Kondo, Y. (2013) Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in Glioblastoma. Cancer Res. 73, 4559-4570
6. Boyer, L.A., Plath, K, Zeitlinger, J., Brambrink, T., Medeiros, L.A., Lee, T.I., Levine, S.S., Wernig, M., Tajonar, A., Ray, M.K., Bell, GW., Otte, A.P., Vidal, M., Gifford, D.K., Young, R.A., and Jaenisch, R. (2006) Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441, 349-353
7. Lee, T.I., Jenner, R.G., Boyer, L.A., Guenther, M.G, Levine, S.S., Kumar, R.M., Chevalier, B., Johnstone, S.E., Cole, M.F., Isono, K, Koseki, H., Fuchikami, T., Abe, K, Murray, H.L., Zucker, J.P., Yuan, B., Bell, G.W., Herbolsheimer, E., Hannett, N.M., Sun, K, Odom, D.T., Otte, A.P., Volkert, T.L., Bartel, D.P., Melton, D.A., Gifford, D.K., Jaenisch, R., and Young, R.A. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125, 301-313
8. Azuara, V., Perry, P., Sauer, S., Spivakov, M., Jorgensen, H.F., John, R.M., Gouti, M., Casanova, M., Warnes, G, Merkenschlager, M., and Fisher, A.G. (2006) Chromatin signatures of pluripotent cell lines. Nat. Cell Biol. 8, 532-538
9. Margueron, R. and Reinberg, D. (2011) The Polycomb complex PRC2 and its mark in life. Nature 469, 343-349
10. Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha, C, Sanda, M.G, Ghosh, D., Pienta, K.J., Sewalt, R.G, Otte, A.P., Rubin, M.A., and Chinnaiyan, A.M. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629
11. Kleer, C.G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S.A., Ghosh, D., Sewalt, R.G, Otte, A.P., Hayes, D.F., Sabel, M.S., Livant, D., Weiss, S.J., Rubin, M.A., and Chinnaiyan, A.M. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606-11611
12. Sneeringer, C.J., Scott, M.P., Kuntz, K.W., Knutson, S.K., Pollock, R.M., Richon, V.M., and Copeland, R.A. (2010) Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107, 20980-20985
13. McCabe, M.T., Graves, A.P., Ganji, G, Diaz, E., Halsey, W.S., Jiang, Y., Smitheman, K.N., Ott, H.M., Pappalardi, M.B., Allen, K.E., Chen, S.B., Della Pietra, A. III, Dul, E., Hughes, A.M., Gilbert, S.A., Thrall, S.H., Tummino, P.J., Kruger, R.G, Brandt, M., Schwartz, B., and Creasy, C.L. (2012) Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109, 2989-2994
14. Morin, R.D., Johnson, N.A., Severson, T.M., Mungall, A.J., An, J., Goya, R., Paul, J.E., Boyle, M., Woolcock, B.W., Kuchenbauer, F., Yap, D., Humphries, R.K., Griffith, O.L., Shah, S., Zhu, H, Kimbara, M., Shashkin, P., Charlot, J.F., Tcherpakov, M., Corbett, R., Tam, A., Varhol, R., Smailus, D., Moksa, M., Zhao, Y., Delaney, A., Qian, H., Birol, I., Schein, J., Moore, R., Holt, R., Horsman, D.E., Connors, J.M., Jones, S., Aparicio, S., Hirst, M., Gascoyne, R.D., and Marra, M.A. (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185
15. Yap, D.B., Chu, J., Berg, T., Schapira, M., Cheng, S.W., Moradian, A., Morin, R.D., Mungall, A.J., Meissner, B., Boyle, M., Marquez, V.E., Marra, M.A., Gascoyne, R.D., Humphries, R.K., Arrowsmith, C.H., Morin, G.B., and Aparicio, S.A. (2010) Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117, 2451-2459
16. Tanaka, S., Miyagi, S., Sashida, G, Chiba, T., Yuan, J., Mochizuki-Kashio, M., Suzuki, Y., Sugano, S., Nakaseko, C, Yokote, K, Koseki, H., and Iwama, A. (2012) Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 120, 1107-1117
17. Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C, Jones, A.V., Waghorn, K, Zoi, K, Ross, F.M., Reiter, A., Hochhaus, A., Drexler, H.G, Duncombe, A., Cervantes, F., Oscier, D., Boultwood, J., Grand, F.H., and Cross, N.C. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42, 722-726
18. Nikoloski, G, Langemeijer, S.M., Kuiper, R.P., Knops, R., Massop, M., Tonnissen, E.R., van der Heijden, A., Scheele, T.N., Vandenberghe, P., de Witte, T., van der Reijden, B.A., and Jansen, J.H. (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42, 665-667
19. Makishima, H., Jankowska, A.M., Tiu, R.V., Szpurka, H., Sugimoto, Y., Hu, Z., Saunthararajah, Y., Guinta, K., Keddache, M.A., Putnam, P., Sekeres, M.A., Moliterno, A.R., List, A.F., McDevitt, M.A., and Maciejewski, J.P. (2010) Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 24, 1799-1804
20. Simon, C, Chagraoui, J., Krosl, J., Gendron, P., Wilhelm, B., Lemieux, S., Boucher, G, Chagnon, P., Drouin, S., Lambert, R., Rondeau, C, Bilodeau, A., Lavallee, S., Sauvageau, M., Hebert, J., and Sauvageau, G (2012) A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 26, 651-656
21. Ntziachristos, P., Tsirigos, A., Van Vlierberghe, P., Nedjic, J., Trimarchi, T., Flaherty, M.S., Ferres-Marco, D., da Ros, V., Tang, Z., Siegle, J., Asp, P., Hadler, M., Rigo, I., De Keersmaecker, K., Patel, J., Huynh, T., Utro, F., Poglio, S., Samon, J.B., Paietta, E., Racevskis, J., Rowe, J.M., Rabadan, R., Levine, R.L., Brown, S., Pflumio, F., Dominguez, M., Ferrando, A., and Aifantis, I. (2012) Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 18, 298-301
22. Sauvageau, M. and Sauvageau, G (2010) Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7, 299-313
23. Ohnishi, K., Semi, K., Yamamoto, T., Shimizu, M., Tanaka, A., Mitsunaga, K., Okita, K., Osafune, K., Arioka, Y., Maeda, T., Soejima, H., Moriwaki, H., Yamanaka, S., Woltjen, K., and Yamada, Y. (2014) Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 156, 663-677
24. Gupta, P.B., Chaffer, C.L., and Weinberg, R.A. (2009) Cancer stem cells: mirage or reality? Nat. Med. 15, 1010-1012
25. Polyak, K. and Weinberg, R.A. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265-273
26. Gupta, P.B., Fillmore, CM, Jiang, G, Shapira, S.D., Tao, K., Kuperwasser, C, and Lander, E.S. (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633-644
27. Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001) Stem cells, cancer, and cancer stem cells. Nature 414, 105-111
28. Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G, and Parada, L.F. (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526
29. Singh, S.K., Hawkins, C, Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D., and Dirks, P.B. (2004) Identification of human brain tumour initiating cells. Nature 432, 396-401
30. Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N.M., Pastorino, S., Purow, B.W., Christopher, N., Zhang, W., Park, J.K., and Fine, H.A. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391-403
31. Lee, J., Son, M.J., Woolard, K., Donin, N.M., Li, A., Cheng, C.H., Kotliarova, S., Kotliarov, Y., Walling, J., Ahn, S., Kim, M., Totonchy, M., Cusack, T., Ene, C, Ma, H, Su, Q., Zenklusen, J.C., Zhang, W., Maric, D., and Fine, H.A. (2008) Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13, 69-80
32. Penuelas, S., Anido, J., Prieto-Sanchez, R.M., Folch, G, Barba, I., Cuartas, I., Garcia-Dorado, D., Poca, M.A., Sahuquillo, J., Baselga, J., and Seoane, J. (2009) TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15, 315-327
33. Cheng, L., Huang, Z., Zhou, W., Wu, Q., Donnola, S., Liu, J.K., Fang, X., Sloan, A.E., Mao, Y., Lathia, J.D., Min, W., McLendon, R.E., Rich, J.N., and Bao, S. (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153, 139-152
34. Trost, M., Sauvageau, M., Herault, O., Deleris, P., Pomies, C, Chagraoui, J., Mayotte, N, Meloche, S., Sauvageau, G, and Thibault, P. (2012) Posttranslational regulation of self-renewal capacity: insights from proteome and phosphoproteome analyses of stem cell leukemia. Blood 120, e17-27
35. Shi, B., Liang, J., Yang, X., Wang, Y., Zhao, Y., Wu, H., Sun, L., Zhang, Y., Chen, Y., Li, R., Zhang, Y., Hong, M., and Shang, Y. (2007) Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol. Cell. Biol. 27, 5105-5119
36. Lee, S.T., Li, Z., Wu, Z., Aau, M., Guan, P., Karuturi, R.K., Liou, Y.C., and Yu, Q. (2011) Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Mol. Cell 43, 798-810
37. Jung, H.Y., Jun, S., Lee, M., Kim, H.C., Wang, X., Ji, H., McCrea, P.D., and Park, J.I. (2013) PAF and EZH2 induce Wnt/beta-catenin signaling hyperactivation. Mol. Cell 52, 193-205
38. Xu, K, Wu, Z.J., Groner, A.C., He, H.H., Cai, C, Lis, R.T., Wu, X., Stack, E.C., Loda, M., Liu, T., Xu, H., Cato, L., Thornton, J.E., Gregory, R.I., Morrissey, C, Vessella, R.L., Montironi, R., Magi-Galluzzi, C, Kantoff, P.W., Balk, S.P., Liu, X.S., and Brown, M. (2012) EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338, 1465-1469
39. Cha, T.L., Zhou, B.P., Xia, W., Wu, Y., Yang, C.C., Chen, C.T., Ping, B., Otte, A.P., and Hung, M.C. (2005) Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310, 306-310
40. Kim, E., Kim, M., Woo, D.H., Shin, Y., Shin, J., Chang, N, Oh, Y.T., Kim, H., Rheey, J., Nakano, I., Lee, C, Joo, K.M., Rich, J.N., Nam, D.H., and Lee, J. (2013) Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23, 839-852
41. He, A., Shen, X., Ma, Q., Cao, J., von Gise, A., Zhou, P., Wang, G, Marquez, V.E., Orkin, S.H., and Pu, W.T. (2012) PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev. 26, 37-42
42. Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P.L., Karuturi, R.K., Tan, P.B., Liu, E.T., and Yu, Q. (2007) Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050-1063
43. Richon, V.M., Johnston, D., Sneeringer, C.J., Jin, L., Majer, C.R., Elliston, K., Jerva, L.F., Scott, M.P., and Copeland, R.A. (2011) Chemogenetic analysis of human protein methyltransferases. Chem. Biol. Drug Des. 78, 199-210
44. Knutson, S.K., Wigle, T.J., Warholic, N.M., Sneeringer, C.J., Allain, C.J., Klaus, C.R., Sacks, J.D., Raimondi, A., Majer, C.R., Song, J., Scott, M.P., Jin, L., Smith, J.J., Olhava, E.J., Chesworth, R., Moyer, M.P., Richon, V.M., Copeland, R.A., Keilhack, H., Pollock, R.M., and Kuntz, K.W. (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nature Chem. Biol. 8, 890-896
45. McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C, Van Aller, GS., Liu, Y., Graves, A.P., Della Pietra, A. 3rd, Diaz, E., LaFrance, L.V., Mellinger, M., Duquenne, C, Tian, X., Kruger, R.G, McHugh, CF., Brandt, M., Miller, W.H., Dhanak, D., Verma, S.K., Tummino, P.J., and Creasy, C.L. (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112
46. Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H., Lin, Y., Gu, J., Ardayfio, O., Zhang, J.H., Yan, X., Fang, J., Mi, Y., Zhang, M., Zhou, T., Feng, G, Chen, Z., Li, G, Yang, T., Zhao, K, Liu, X., Yu, Z., Lu, C.X., Atadja, P., and Li, E. (2012) Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl Acad. Sci. U.S. A. 109, 21360-21365
47. Konze, K.D., Ma, A., Li, F., Barsyte-Lovejoy, D., Parton, T., Macnevin, C.J., Liu, F., Gao, C, Huang, X.P., Kuznetsova, E., Rougie, M., Jiang, A., Pattenden, S.G, Norris, J.L., James, L.I., Roth, B.L., Brown, P.J., Frye, S.V., Arrowsmith, C.H., Hahn, K.M., Wang, G.G., Vedadi, M., and Jin, J. (2013) An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324-1334
48. Knutson, S.K., Kawano, S., Minoshima, Y., Warholic, N.M., Huang, K.C., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G, Kumar, N., Wigle, T.J., Klaus, C.R., Allain, C.J., Raimondi, A., Waters, N.J., Smith, J.J., Porter-Scott, M., Chesworth, R., Moyer, M.P., Copeland, R.A., Richon, V.M., Uenaka, T., Pollock, R.M., Kuntz, K.W., Yokoi, A., and Keilhack, H. (2014) Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma. Mol. Cancer Ther. 13, 842-854
49. Kim, W., Bird, GH., Neff, T., Guo, G, Kerenyi, M.A., Walensky, L.D., and Orkin, S.H. (2013) Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol. 9, 643-650
50. Bracken, A.P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G, Beekman, C, Theilgaard-Monch, K, Minucci, S., Porse, B.T., Marine, J.C., Hansen, K.H., and Helin, K. (2007) The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21, 525-530
51. Fan, T., Jiang, S., Chung, N, Alikhan, A., Ni, C, Lee, C.C., and Hornyak, T.J. (2011) EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol. Cancer Res. 9, 418-429
52. Birney, E., Stamatoyannopoulos, J.A., Dutta, A., Guigo, R., Gingeras, T.R., Margulies, E.H., Weng, Z., Snyder, M., Dermitzakis, E.T., Thurman, R.E., Kuehn, M.S., Taylor, CM., Neph, S., Koch, CM, Asthana, S., Malhotra, A., Adzhubei, I., Greenbaum, J.A., Andrews, R.M., Flicek, P., Boyle, P.J., Cao, H., Carter, N.P., Clelland, G.K., Davis, S., Day, N., Dhami, P., Dillon, S.C., Dorschner, M.O., Fiegler, H., Giresi, P.G, Goldy, J., Hawrylycz, M., Haydock, A., Humbert, R., James, K.D., Johnson, B.E., Johnson, E.M., Frum, T.T., Rosenzweig, E.R., Karnani, N., Lee, K, Lefebvre, G.C., Navas, P.A., Neri, F., Parker, S.C., Sabo, P.J., Sandstrom, R., Shafer, A., Vetrie, D., Weaver, M., Wilcox, S., Yu, M., Collins, F.S., Dekker, J., Lieb, J.D., Tullius, T.D., Crawford, G.E., Sunyaev, S., Noble, W.S., Dunham, I., Denoeud, F., Reymond, A., Kapranov, P., Rozowsky, J., Zheng, D., Castelo, R., Frankish, A., Harrow, J., Ghosh, S., Sandelin, A., Hofacker, I.L., Baertsch, R., Keefe, D., Dike, S., Cheng, J., Hirsch, H.A., Sekinger, E.A., Lagarde, J., Abril, J.F., Shahab, A., Flamm, C, Fried, C, Hackermuller, J., Hertel, J., Lindemeyer, M., Missal, K, Tanzer, A., Washietl, S., Korbel, J., Emanuelsson, O., Pedersen, J.S., Holroyd, N., Taylor, R., Swarbreck, D., Matthews, N., Dickson, M.C., Thomas, D.J., Weirauch, M.T., Gilbert, J., Drenkow, J., Bell, I., Zhao, X., Srinivasan, K.G, Sung, W.K., Ooi, H.S., Chiu, K.P., Foissac, S., Alioto, T., Brent, M., Pachter, L., Tress, M.L., Valencia, A., Choo, S.W., Choo, C.Y., Ucla, C, Manzano, C, Wyss, C, Cheung, E., Clark, T.G, Brown, J.B., Ganesh, M., Patel, S., Tammana, H., Chrast, J., Henrichsen, C.N., Kai, C, Kawai, J., Nagalakshmi, U., Wu, J., Lian, Z., Lian, J., Newburger, P., Zhang, X., Bickel, P., Mattick, J.S., Carninci, P., Hayashizaki, Y., Weissman, S., Hubbard, T., Myers, R.M., Rogers, J., Stadler, P.F., Lowe, T.M., Wei, C.L., Ruan, Y., Struhl, K, Gerstein, M., Antonarakis, S.E., Fu, Y., Green, E.D., Karaoz, U., Siepel, A., Taylor, J., Liefer, L.A., Wetterstrand, K.A., Good, P.J., Feingold, E.A., Guyer, M.S., Cooper, GM., Asimenos, G, Dewey, C.N., Hou, M., Nikolaev, S., Montoya-Burgos, J.I., Loytynoja, A., Whelan, S., Pardi, F., Massingham, T., Huang, H., Zhang, N.R., Holmes, I., Mullikin, J.C., Ureta-Vidal, A., Paten, B., Seringhaus, M., Church, D., Rosenbloom, K, Kent, W.J., Stone, E.A., Batzoglou, S., Goldman, N., Hardison, R.C., Haussler, D., Miller, W., Sidow, A., Trinklein, N.D., Zhang, Z.D., Barrera, L., Stuart, R., King, D.C., Ameur, A., Enroth, S., Bieda, M.C, Kim, J., Bhinge, A.A., Jiang, N., Liu, J., Yao, F., Vega, V.B., Lee, C.W., Ng, P., Shahab, A., Yang, A., Moqtaderi, Z., Zhu, Z., Xu, X., Squazzo, S., Oberley, M.J., Inman, D., Singer, M.A., Richmond, T.A., Munn, K.J., Rada-Iglesias, A., Wallerman, O., Komorowski, J., Fowler, J.C., Couttet, P., Bruce, A.W., Dovey, O.M., Ellis, P.D., Langford, CF., Nix, D.A., Euskirchen, G, Hartman, S., Urban, A.E., Kraus, P., Van Calcar, S., Heintzman, N., Kim, T.H., Wang, K, Qu, C, Hon, G, Luna, R., Glass, CK., Rosenfeld, M.G, Aldred, S.F., Cooper, S.J., Halees, A., Lin, J.M., Shulha, H.P., Zhang, X., Xu, M., Haidar, J.N., Yu, Y., Ruan, Y., Iyer, V.R., Green, R.D., Wadelius, C, Farnham, P.J., Ren, B., Harte, R.A., Hinrichs, A.S., Trumbower, H., Clawson, H., Hillman-Jackson, J., Zweig, A.S., Smith, K., Thakkapallayil, A., Barber, G, Kuhn, R.M., Karolchik, D., Armengol, L., Bird, C.P., de Bakker, P.I., Kern, A.D., Lopez-Bigas, N., Martin, J.D., Stranger, B.E., Woodroffe, A., Davydov, E., Dimas, A., Eyras, E., Hallgrimsdottir, I.B., Huppert, J., Zody, M.C., Abecasis, G.R., Estivill, X., Bouffard, G.G., Guan, X., Hansen, N.F., Idol, J.R., Maduro, V.V., Maskeri, B., McDowell, J.C., Park, M., Thomas, P.J., Young, A.C., Blakesley, R.W., Muzny, D.M., Sodergren, E., Wheeler, D.A., Worley, K.C., Jiang, H., Weinstock, GM., Gibbs, R.A., Graves, T., Fulton, R., Mardis, E.R., Wilson, R.K., Clamp, M., Cuff, J., Gnerre, S., Jaffe, D.B., Chang, J.L., Lindblad-Toh, K., Lander, E.S., Koriabine, M., Nefedov, M., Osoegawa, K., Yoshinaga, Y., Zhu, B., and de Jong, P.J. (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447, 799-816
53. Wang, K.C., Yang, Y.W., Liu, B., Sanyal, A., Corces-Zimmerman, R., Chen, Y., Lajoie, B.R., Protacio, A., Flynn, R.A., and Gupta, R.A. (2011) A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 472, 120-124
54. Prensner, J.R. and Chinnaiyan, A.M. (2011) The emergence of lncRNAs in cancer biology. Cancer Discov. 1, 391-407
55. Hu, W., Alvarez-Dominguez, J.R., and Lodish, H.F. (2012) Regulation of mammalian cell differentiation by long non-coding RNAs. EMBO Rep. 13, 971-983
56. Guttman, M., Donaghey, J., Carey, B.W., Garber, M., Grenier, J.K., Munson, G, Young, G, Lucas, A.B., Ach, R., Bruhn, L., Yang, X., Amit, I., Meissner, A., Regev, A., Rinn, J.L., Root, D.E., and Lander, E.S. (2011) lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 477, 295-300
57. Khalil, A.M., Guttman, M., Huarte, M., Garber, M., Raj, A., Rivea Morales, D., Thomas, K., Presser, A., Bernstein, B.E., van Oudenaarden, A., Regev, A., Lander, E.S., and Rinn, J.L. (2009) Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl Acad. Sci. USA 106, 11667-11672
58. Zhao, J., Ohsumi, T.K., Kung, J.T., Ogawa, Y., Grau, D.J., Sarma, K., Song, J.J., Kingston, R.E., Borowsky, M., and Lee, J.T. (2010) Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol. Cell 40, 939-953
59. Goff, L.A. and Rinn, J.L. (2013) Poly-combing the genome for RNA. Nat. Struct. Mol. Biol. 20, 1344-1346
60. Guttman, M. and Rinn, J.L. (2012) Modular regulatory principles of large non-coding RNAs. Nature 482, 339-346